Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angel-J2: Long-term Setaneo (Sepetaprost) in Glaucoma and Ocular Hypertension
NCT05503901Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sepetaprost in open-angle glaucoma (OAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Aug 2022; status: completed.
02
Drugs
sepetaprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT05503901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503901.